

Attachment to Notice of Allowance

1. Applicants' arguments after final of 2/07/2011 is acknowledged.

Status of Claims

2. Claims 11-13 and 16-32 are pending. Claims 11-13, 16-18 and 20 are under consideration. Claims 19 and 21-32 have been withdrawn.

Rejections Withdrawn

3. Rejection of claims 11-13, 16-18 and 20 under 35 U.S.C. 103 (a) made in paragraph 11 of the office action mailed 10/07/2010 is withdrawn in view of applicants' arguments after final of 2/07/2011.

EXAMINER'S AMENDMENT

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kenneth H. Sonnenfeld reg# 33,285 on 3/11/2011.

The application has been amended as follows:

Please cancel claims 12, 19 and 21-32.

Please amend claims 11 and 18 as following:

11. (**Currently Amended**) A conjugated vaccine comprising ~~an~~ **bacterial capsular polysaccharide** antigen that has been conjugated to Fragment C, wherein the Fragment C does not exist in the conjugate vaccine as part of a whole tetanus toxoid molecule, and wherein the conjugate vaccine does not increase a patient's anti-tetanus titer response.
18. (**Currently Amended**) the conjugate vaccine according to claim ~~11~~ **17**, wherein the protease is papain.

Allowable Subject Matter

5. Claims 11, 13, 16-18 and 20 are allowed and renumbered 1-6 respectively.

The following is an examiner's statement of reasons for allowance:

The claims are drawn to a conjugated vaccine comprising a bacterial capsular polysaccharide antigen that has been conjugated to Fragment C, wherein the Fragment C does not exist in the conjugate vaccine as part of a whole tetanus toxoid molecule, and wherein the conjugate vaccine does not increase a patient's anti-tetanus titer response.

The closest prior art Michon *et al.* US 6,602,508 B2 and Chatfield WO 99/15671 fail to teach or disclose the vaccine of claim 11.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khatol S. Shahnan-Shah whose telephone number is (571)-272-0863. The examiner can normally be reached on Mon, Wed 12:30-6:30 pm, Thurs-Fri 12:30-4:30pm pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary B. Nickol can be reached on (571)-272 0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the

Application/Control Number: 10/562,256

Page 4

Art Unit: 1645

automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Khatol S Shahnan-Shah/

Examiner, Art Unit 1645

March 11, 2011

/Gary B. Nickol /

Supervisory Patent Examiner, Art Unit 1646